In this short video, Dr. Suresh Ramalingam discusses the rationale for targeting HER2 genetic aberrations in patients with NSCLC.
Supported by an educational grant from Daiichi Sankyo.
Oncology Education | All Posts
In this short video, Dr. Suresh Ramalingam discusses the rationale for targeting HER2 genetic aberrations in patients with NSCLC.
Supported by an educational grant from Daiichi Sankyo.